PSYCHOVEGETATIVE, ASTHENIC AND COGNITIVE IMPAIRMENT IN CONNECTIVE TISSUE DYSPLASIA: CHOICE OF OPTIMAL THERAPY
- 作者: Duma SN1, Lisichenko OV1, Luk'yanova GV1, Duma SN1, Lisichenko OV1, Lukyanova GV1
-
隶属关系:
- 期: 编号 7 (2012)
- 页面: 131-135
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/279544
- ID: 279544
如何引用文章
全文:
详细
The article presents the results of the evaluation of the efficacy and safety of use of acetyl-L-carnitine (Carnicetine) in asthenic, psychovegetative and cognitive impairment in 60 patients with connective tissue dysplasia in comparison with non-pharmacological and bracing therapy. It was found that the therapy with Carnicetine reduces the manifestations of asthenia, reduces neurological and vegetative symptoms with significant improvement in all cognitive scales.
参考
- Кадурина Т.И., Горбунова В.Н. Дисплазия соединительной ткани. Руководство для врачей. СПб., 2009. 714 с.
- Копелевич В.М. Применение ацетил L-карнитина (карницитин) в клинической практике. Методическое пособие. М., 2010, 28 с.
- Копелевич В.М. Витаминоподобные соединения L-карнитина и ацетил-Lкарнитина:от биохимических исследований к медицинскому применению // Укр. биохим. журн. 2005. № 77. С. 24-45.
- Нечаева Г.И., Викторова И.А. Дисплазии соединительной ткани: терминология, диагностика, тактика ведения пациентов. Омск, 2007. 188 с.
- Сухоруков В.С. К разработке рациональных основ энерготропной терапии // Рациональная фармакотерапия 2007. № 2. С. 40-47.
- Торшин И.Ю., Громова О.А. Дисплазии соединительной ткани, магний и нуклеотидные полиморфизмы // Кардиология 2008. № 10. С. 57-64.
- Шабалов Н.П., Арсентьев В.Г. Педиатрия: национальное руководство. М., 2009. № 1. С. 298-320.
- Aliev G, Liu J, ShenkJC, et al. Neuronal mitochondrial energy metabolism. Neuropharmacol 2008;55(2):223-9.
- Angelucci L, Ramacci MT, Taglialatela G, et al. Nerve growth factor binding in agedrat centralnervous system:effect of acetyl-L-carnitine. J Neurosci Res 1988;20:491-96.
- Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983;63:1420-80.
- Castorina M, Ambrosini AM, Pacific L, et al. Agt-dependent loss of NMDA receptors in hippocampus, stpiatum andfrontal cortex of the rat: prevention by acetyl-Lcarnitine. Neurochem Res 1994;19:795-98.
- Harsing LG Jr, Sershen H, Toth E, et al. Acetyl-Lcarnitine releases dopamine in ratcorpus striatum: an in vivo microdialysis study. Eur J pharmacol 1992;218:117-21.
- Imperato A, Rammacci MT, Angelucci L. Acetyl-Lcarnitine enhances acetylcholine release in the striatum and hippocampus of awakefreely moving rats. Neurosci Lett 1989;107:251-55.
- Liu J, Head E, Kuratsune H, et al. Comparison of the effekts of L-carnitine Ann NY Acad Sci 2004;1033:117-31.
- Pettegrew JW, Levine J, McClure RJ, Acetyl-Lcarnitine physical-chemical, metabolic,andtherapeutic properties: relevance for its mode of action in Alzheimers disease and geriatric depression. Molecul Psychiat 2000;5:616-32.
- Tempesta E, Janiri L, Pirrongelli C. Stereospecific effects of acetylcarnitineon the spontaneous activity of brainstem neurones and their responses to acetyicholine and serotonin. Neuropharmacology 1985;24:43-50.
- Tsuji A. Functional relevance of carnitine transporter OCTN2 tobrain distribution of L-carnitine and acetyl-Lcarnitine across the blood-brainbarrier. J Neirochem 2001;79:959-69.